110 results about "High risk populations" patented technology

The present invention offers a comprehensive solution to care management which aggregates, integrates and stores clinical information from disparate sources. The system finds at-risk individuals before they experience preventable, high-cost medical events and stratifies high risk populations according to clinical criteria, which can include severity of disease states and co-morbidities. The system also compares the actual care an individual is receiving to established standards of clinical excellence and, if necessary, suggests pertinent medical care considerations to improve the care of medically mismanaged individuals. Another feature of the present invention may include a secure, patient-specific Web page which is automatically populated with a patient's own clinical information and can be personalized with customized, relevant healthcare information. The system allows users to design, facilitate and monitor clinical care plans and increase communications among physicians, nurses and patients. The system also predicts and analyzes the outcome of disease or case management for populations and individual patients.

The invention belongs to the technical field of tumor medicine, and particularly discloses an autoantibody joint detection ELISA kit for screening early esophageal cancer. The kit comprises a solid-phase carrier and tumor-associated antigens coated on the solid-phase carrier, wherein the tumor-associated antigens are EYA4, ABL1, ATF2, CD38, NOTCH1, ZBTB20, BCL2L1 and P53. Furthermore, the kit alsocomprises a sample diluent, a second antibody, a second antibody diluent, positive control serum, negative control serum, a color developing solution, a stop solution and a washing solution. The ELISA kit provided by the invention can effectively detect esophageal cancer, especially early esophageal cancer, has the detection sensitivity of 94% and the specificity of 79%, can be used for large-scale screening of asymptomatic people in high-incidence areas of esophageal cancer, and is beneficial to screening and early discovery of asymptomatic high-risk population.

The invention discloses a chronic disease management system and a realization method thereof on the basis of cloud computing and mobile Internet technology, and belongs to the computer science field.The system comprises a chronic disease management and health service platform, an individual self-service management system, a medical institution service management system, a health center service management system and a doctor service management system, wherein the individual self-service management system, the medical institution service management system, the health center service management system and the doctor service management system are connected with the chronic disease management and health service platform. The individual self-service management system is connected with the doctorservice management system and the medical institution service management system. The doctor service management system is connected with the health center service management system. On the basis of amulti-layer loose and coupled high-scalability configuration design and a service exchange framework technique, the management system based on cloud computing and mobile Internet technology improves the work efficiency of doctors, achieves effective disease management and health management for patients suffering from chronic diseases and high-risk populations, and reduces the incidence rate, the hospitalization rate, the re-hospitalization rate and the mortality rate of chronic diseases such as heart failures.

The invention discloses an application method of serum Exosomes-derived long non-coding RNA (long no-coding RNA, LncRNA) PRKAG2-AS1, namely, the serum Exosomes-derived LncRNA PRKAG2-AS1 is used for preparing drugs for the screening and early diagnosis of high-risk population with gliomas or prognosis preparations for patients with gliomas. Through researching, a situation that RNA is extracted after Exosomes are separated from serums of patients with gliomas, then the RNA is subjected to reverse transcription and real-time fluorescent quantitative analysis, and the expression level of LncRNA PRKAG2-AS1 drops is verified. The specificity of the preparation disclosed by the invention and for the early diagnosis of gliomas can reach 85.7%, and the sensitivity reaches 88.2%. Through detecting the expression level of LncRNA PRKAG2-AS1 in serum Exosomes of patients with gliomas, the early and rapid noninvasive diagnosis on the patients with gliomas is implemented.

The invention discloses a construction method and a construction system for a type 2 diabetes mellitus risk assessment model. The method comprises the following steps that: (1) selecting an SNP (Single Nucleotide Polymorphisms) locus related to type 2 diabetes mellitus; (2) calculating the risk degree, i.e., an OR (Odds Ratio) value, of the SNP locus; (3) calculating the frequency of the SNP locus in an East Asia population; (4) calculating the epidemiology prevalence rate of the type 2 diabetes mellitus; and (5) according to a Bayesian algorithm and a Hardy-Weinberg equilibrium principle, constructing the risk assessment model. The model of the invention calculates the mathematical expectation value and the OR value of the risk allele amount of the population, the epidemiology prevalence rate of the type 2 diabetes mellitus is combined to obtain the average prevalence rate and the confidence interval of a group on the basis of inheritance, a new construction method for the type 2 diabetes mellitus risk assessment model is provided, so that the prevalence risk of the type 2 diabetes mellitus more approaches to a true situation, and a result is more scientific and reasonable. By use of the method, high-risk population screening accuracy is improved, the prevalence rate of the type 2 diabetes mellitus is expected to be lowered, and a great quantity of expenditures can be saved for the nation and society so as to benefit the nation and the people.